Advertisement
Paper| Volume 37, ISSUE 4, P529-532, February 15, 1985

Treatment with stanozolol before thrombolysis in patients with arterial occlusions

DOI:https://doi.org/10.1016/0049-3848(85)90098-2
Treatment with stanozolol before thrombolysis in patients with arterial occlusions
Previous ArticleHirudin insensitive thrombin-stimulated platelet release
Next ArticleA sensitive and specific assay for plasminogen activators
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The administration of the anabolic steroid stanazolol during 7,8 days as pretreatment before thrombolytic therapy of acute or subacute arterial occlusions enhances the fibrinolytic potential significantly.On average the plasminogen increased from 101% to 133%, the euglobulin lysis time after venous stasis was shortened and the α2-antiplasmin remained constant. This effect could be favourable to prepare patients undergoing thrombolytic treatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Davidson J.F.
        • Lochhead M.
        • McDonald G.A.
        • McNicol G.P.
        Fibrinolytic enhancement by stanozolol: A double blind trial.
        Brit. J. Haemat. 1972; 22: 543-559
        • Jarrett P.E.M.
        • Morland M.
        • Browse N.L.
        Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.
        Brit. Med. J. 1977; 1: 933-934
        • Kluft C.
        • Preston F.E.
        • Malia R.G.
        • Wijngaards G.
        Characterization of the effect of stanozolol on fibrinolytic parameters in healthy volunteers.
        in: Progress in Fibrinolysis. Vol 6. Churchill Livingstone, Edinburgh, London, Melbourne, New York1983: 513-518
        • Preston F.E.
        • Burakowski N.R.
        • Malia R.G.
        The fi- brinolytic response to stanozolol in normal subjects.
        Thromb. Res. 1981; 22: 543-551
        • Friberger P.
        • Knos M.
        • Gustavsson S.
        • Aurell L.
        • Claeson G.
        Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.
        Haemostasis. 1978; 7: 138-145
        • Kabi Diagnostica
        Determination of plasminogen in plasma with S-2251.
        in: Laboratory Instruction. April 1977
        • Teger-Nilsson A.C.
        • Friberger P.
        • Gyzander E.
        Deter- mination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.
        Scand. J. Clin. Lab. Invest. 1977; 37: 403-409
        • Kabi Diagnostica
        Determination of antiplasmin in plasma with S-2251.
        in: Laboratory Instruction. April 1977
        • Laemmle G.
        • Noll G.
        • Christe M.
        • Fritschi J.
        • Czendlik C.
        • Marbet G.A.
        • Biland L.
        • Da Silva A.
        • Huber P.
        • Widmer L.K.
        • Ritz R.
        • Schmitt H.E.
        • Duckert F.
        Systemische Thrombolyse arterieller Verschlüsse der unte- ren Extremitäten. Vergleich verschiedener Behandlungssche-mata.
        Schweiz. med. Wschr. 1983; 113: 1570-1576
        • Marbet G.A.
        • Eichlisberger R.
        • Duckert F.
        • Da Silva M.A.
        • Biland L.
        • Widmer L.K.
        • Ritz R.
        • Schmitt H.E.
        Sequential treatment of arterial occlusions with porcine plasmin and low dose streptokinase.
        Thromb. Haemostas. 1982; 48: 187-189
        • Preston F.E.
        • Malia R.G.
        • Greaves M.
        • Wijngaards G.
        • Kluft C.
        The effect of stanozolol on thrombotic risk factors in healthy individuals.
        in: Progress in Fibrinolysis. Vol. 6. Churchill Livingstone, Edinburgh, London, Melbourne, New York1983: 519-523

      Article info

      Publication history

      Accepted: November 26, 1984
      Received: July 23, 1984

      Identification

      DOI: https://doi.org/10.1016/0049-3848(85)90098-2

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX